ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tiny study tests Tumor-Injected drug plus immunotherapy for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab (Keytruda) in 6 people with advanced head and neck cancer, melanoma, or triple-negative breast cancer. The main goal was to check safety and side …
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New combo therapy shows promise for tough head and neck cancers
Disease control CompletedThis phase 2 trial tested a combination of a short, intense course of radiation (quad-shot) and the immunotherapy drug pembrolizumab in 21 people with advanced, recurrent, or metastatic head and neck cancer. The goal was to see if the combination could shrink tumors and be safe. …
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis study tested a combination of two drugs, duvelisib and docetaxel, in 26 people with head and neck cancer that had returned or spread and could not be cured. The goal was to see if the combination could shrink tumors or slow the disease. The approach aims to control the cance…
Matched conditions: ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Glenn J. Hanna • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC